OptiBiotix Health Plc

OptiBiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; SlimBiome Medical, a natural supplement for weight management; CholBiome, a food supplement for maintaining healthy levels of cholesterol; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galactooligosaccharid that is used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; WellBiome, a functional fibre and mineral blend that supports health & wellbeing by promoting the diversity of the gut microbiome; and Sweetbiotix, a sweetener for use in food and beverages. The company's products prevents and manages chronic lifestyle diseases, including obesity, hypercholesterolemia and lipid profiles, and diabetes. OptiBiotix Health Plc was founded in 2012 and is headquartered in York, the United Kingdom.

OptiBiotix Health Plc trades as OPBXF on OTC. The company is classified in Healthcare / Biotechnology and reports in USD.

The current profile places the business in Biotechnology. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $457,000 of revenue and $2.59M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

OptiBiotix Health Plc can be compared against peers such as American Hemp Ventures, Inc., Biofrontera AG, OKYO Pharma Limited, TPCO Holding Corp., Kadimastem Ltd, Organicell Regenerative Medicine, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $20.06M, beta of 1.75, and return on equity of +23.7%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

OPBXF currently shows total debt of $0 and beta of 1.75. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.optibiotix.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.